Compare BRID & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRID | GNLX |
|---|---|---|
| Founded | 1932 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.0M | 113.6M |
| IPO Year | 1995 | 2022 |
| Metric | BRID | GNLX |
|---|---|---|
| Price | $7.38 | $2.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $19.80 |
| AVG Volume (30 Days) | 3.0K | ★ 156.4K |
| Earning Date | 03-06-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $174,257,000.00 | $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $7.00 | $1.99 |
| 52 Week High | $8.84 | $8.54 |
| Indicator | BRID | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 46.57 | 38.11 |
| Support Level | N/A | $2.33 |
| Resistance Level | $8.07 | $3.00 |
| Average True Range (ATR) | 0.32 | 0.16 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 14.95 | 5.08 |
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The two business segments are: the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches, among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, mass merchandise, and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.